CureVac

EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Retrieved on: 
Freitag, Mai 3, 2024
University, Part, CMO, Federal republic, Research, Cancer, Federal Patent Court (Germany), Vaccine, Business, Webcast, BioNTech, District court, Whole genome sequencing, Vaccination, Public, WHO, Hearing loss, Cardiology, Animal, EP 1, Omicron, GSK, Systems biology, Workforce, Infection, Messenger, Federal court, Therapy, Data monitoring committee, Safety, Monroe Dunaway Anderson, CVAC, Justice, RNA, Astrocytoma, Motion, Human, CureVac, Pandemic, GMP, Sąd rejonowy, SARS-CoV-2, Business development, Epitope, MD, Acuitas Therapeutics, DSMB, Ageing, Patent, Patient, Neurology, Operating cost, H5N1, MD Anderson Cancer Center, PPA, Interim, MBA, Antigen, COVID-19, Amgen

ET / 3 p.m. CET

Key Points: 
  • ET / 3 p.m. CET
    TÜBINGEN, Germany/BOSTON, USA – April 24, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the fourth quarter and full-year 2023 and provided a business update.
  • “We closed out 2023 on a sturdy footing and are poised to advance strongly through 2024 with strategic initiatives to make CureVac fit-for-purpose.
  • Thaminda Ramanayake was appointed to the CureVac Management Team as Chief Business Officer effective June 1, 2024.
  • Mr. Ramanayake joins CureVac from Affini-T Therapeutics, where he served as Chief Business Officer and was responsible for creating the company’s business development organization.

EQS-News: CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

Retrieved on: 
Freitag, Mai 3, 2024
University, Berea College, Hearing loss, Cardiology, CVAC, Johnson & Johnson, Business development, Research, Business, CureVac, Neurology, Systems biology, Infection, Messenger, MBA, Therapy, Amgen, Pharmaceutical industry

Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas

Key Points: 
  • Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas
    TÜBINGEN, Germany/BOSTON, USA – April 24, 2024 — CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Thaminda Ramanayake has been appointed to the role of Chief Business Officer, effective June 1, 2024.
  • “Thaminda’s extensive experience in advancing corporate strategy, business development and strengthening strategic partnerships in specific areas will be a tremendous asset to CureVac as we work to progress best-in-class mRNA vaccines and medicines across multiple therapeutic areas,” said Dr. Alexander Zehnder, Chief Executive Officer of CureVac.
  • He joins CureVac from Affini-T Therapeutics, where he served as Chief Business Officer and was responsible for creating the company’s business development organization.
  • With an educational background in both immunology and business, Mr. Ramanayake began his career as a scientist at Johnson & Johnson and later held a succession of Wall Street business development and consulting roles.

EQS-News: CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

Retrieved on: 
Freitag, Mai 3, 2024
University, Cell, Monroe Dunaway Anderson, CVAC, Malignancy, MD, RNA, Vaccine, IND, CureVac, Patient, Collaboration, MD Anderson Cancer Center, Assistant, Messenger, Antigen, Evolution, Drug discovery, Therapy, Whole genome sequencing, Investigational New Drug

Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need

Key Points: 
  • Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need
    MD Anderson responsible for leading initial Phase 1/2 studies; CureVac retains worldwide exclusive rights to late-stage development, commercialization, or partnering of cancer vaccine candidates
    TÜBINGEN, Germany/HOUSTON, Texas, USA – April 16, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and The University of Texas MD Anderson Cancer Center today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
  • The collaboration creates strong synergies between CureVac’s unique end-to-end capabilities for cancer antigen discovery, mRNA design, and manufacturing and MD Anderson’s expertise in cancer antigen discovery and validation, translational drug development, and clinical research.
  • The collaboration will focus on the development of differentiated cancer vaccine candidates in selected hematological and solid tumor indications with high unmet medical need.
  • “We are excited for cancer vaccines to potentially emerge as an essential therapeutic tool in the future,” Shukla said.

EQS-News: CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

Retrieved on: 
Freitag, Mai 3, 2024
Ageing, Infection, H5N1, Messenger, Human, CureVac, CVAC, Influenza, GSK, Safety, Virus, Vaccine

The H5N1 avian influenza virus is considered a potential future pandemic threat, known to sporadically cross species from its original bird host to other animal hosts and humans.

Key Points: 
  • The H5N1 avian influenza virus is considered a potential future pandemic threat, known to sporadically cross species from its original bird host to other animal hosts and humans.
  • The monovalent vaccine candidate is based on CureVac’s proprietary second-generation mRNA backbone and encodes an influenza A H5-antigen.
  • In the initial Phase 1 dose-escalation part of the study, up to five dose levels will be assessed compared to a placebo control.
  • It focuses on applying CureVac’s mRNA-technology to the development of new products for infectious disease targets.

EQS-News: CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

Retrieved on: 
Mittwoch, April 10, 2024
GSK, Ageing, CureVac, CVAC, Antigen, Messenger, Candidate, Safety, Vaccine

The multivalent candidate was selected from a comprehensive Phase 1 part, which tested vaccine candidates with up to eight separate mRNA constructs per candidate.

Key Points: 
  • The multivalent candidate was selected from a comprehensive Phase 1 part, which tested vaccine candidates with up to eight separate mRNA constructs per candidate.
  • Targeted optimizations to further improve immune responses against influenza B strains will be tested in an additional Phase 2 study.
  • “The Phase 2 interim data show that CureVac’s highly effective and flexible mRNA technology platform puts us on the right track to advance our joint seasonal influenza vaccine program,” said Dr. Myriam Mendila, Chief Development Officer of CureVac.
  • For older adults, immune responses were compared to a high dose seasonal flu vaccine.

Global Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Dienstag, Februar 27, 2024
Biotechnology, Health, Genetics, Stem Cells, Pharmaceutical, Therapy, Incidence, Tissue engineering, EMA, Regenerative medicine, USD, FDA, Partnership, ATMP, Cell, CDMO, Gene therapy, COVID-19, Disorder, Patient, Clinical trial, CureVac, CureVac COVID-19 vaccine, Tissue, Research, Pharmaceutical industry

The "Global Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report by Product (Gene Therapy, Cell Therapy), Phase, Indication, Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report by Product (Gene Therapy, Cell Therapy), Phase, Indication, Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global advanced therapy medicinal products CDMO market is expected to reach USD 18.8 billion by 2030 and is expected to register a CAGR of 18.92% from 2024 to 2030, owing to rising clinical trials for advanced therapy medicinal products and the increasing awareness among researchers about the benefits of advanced therapies, driving the advanced therapy medicinal products (ATMP) CDMO market growth.
  • Similarly, gene and cell therapy are attracting a lot of patients for the treatment of rare diseases, whose incidence is rising globally.
  • In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe & efficient gene therapy products.

WestGene Spearheads Oncology Breakthroughs at the 3rd mRNA-Based Therapeutics Summit

Retrieved on: 
Mittwoch, Januar 24, 2024
Speech, Therapy, Research, Nasopharyngeal carcinoma, Summit, IIT, NKT, AI, Government, EMA, BioNTech, CureVac, Cancer, Acquisition, WHO, Drug development, Safety, Intellectual property, Toxicity, Patent, Merck, Messenger, HBV, LNP, Vaccine, Colorectal cancer, CEPI

CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.

Key Points: 
  • CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.
  • The Summit, held January 23-25, is a key event in the field of mRNA drug development, attracting over 200 specialists from various parts of the world.
  • Founded by two visionary scientists, Dr. Wei Yuquan and Dr. Xiangrong Song, WestGene Biotech is dedicated to pioneering the field of mRNA therapeutics.
  • This project, along with its extensive pipeline, positions WestGene at the forefront of biopharmaceutical innovation and research.

WestGene Spearheads Oncology Breakthroughs at the 3rd mRNA-Based Therapeutics Summit

Retrieved on: 
Mittwoch, Januar 24, 2024
Speech, Therapy, Research, Nasopharyngeal carcinoma, Multimedia, Summit, IIT, NKT, AI, Government, EMA, BioNTech, CureVac, Cancer, Acquisition, WHO, Drug development, Safety, Intellectual property, Toxicity, Patent, Merck, Messenger, HBV, LNP, Vaccine, Colorectal cancer, CEPI

CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.

Key Points: 
  • CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.
  • Renowned for her pivotal role in mRNA research, Dr. Xiangrong Song, co-founder and CEO of WestGene, presented the latest advances in the company's oncology sector, with a special focus on mRNA-based cancer vaccines.
  • The Summit, held January 23-25, is a key event in the field of mRNA drug development, attracting over 200 specialists from various parts of the world.
  • Founded by two visionary scientists, Dr. Wei Yuquan and Dr. Xiangrong Song, WestGene Biotech is dedicated to pioneering the field of mRNA therapeutics.

EQS-News: CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

Retrieved on: 
Freitag, Januar 5, 2024
Messenger, CVAC, Vaccine, Ageing, Vaccination, Omicron, GSK, COVID-19, Interim, CureVac, Safety

Both vaccine candidates are being developed in collaboration with GSK.

Key Points: 
  • Both vaccine candidates are being developed in collaboration with GSK.
  • Selected data can be reviewed in the presentation associated with this press release.
  • All three of the dose levels tested were below those used in mRNA-based COVID-19 vaccines licensed in the U.S. and EU.
  • “These positive Phase 2 data continue to strongly validate the competitiveness of our proprietary mRNA-technology platform and second-generation mRNA backbone in comparison to a licensed mRNA-based vaccine,” said Dr. Myriam Mendila, Chief Development Officer of CureVac.

EQS-News: CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Retrieved on: 
Dienstag, Dezember 26, 2023
BioNTech, CVAC, Federal court, Patent, Federal Patent Court (Germany), Messenger, COVID-19, CureVac, Bird, Vaccine, Justice, Sąd rejonowy, COVID-19 vaccine, EP 1, Intellectual property, LLP

CureVac will appeal before the German Federal Court of Justice.

Key Points: 
  • CureVac will appeal before the German Federal Court of Justice.
  • The ruling represents a first decision on validity in ongoing patent litigation between CureVac and BioNTech SE in Germany, which involves a total of eight CureVac intellectual property rights.
  • “We consider the patent court’s decision unfortunate also in view of the positive preliminary opinion on EP 1 857 122 B1 the court provided earlier this year.
  • The decision is only one of many that will be made regarding the use of CureVac’s intellectual property in the development of Comirnaty®.